Jean‐François Martini

机构：Pfizer (United States)

发表论文 98 篇 · 总被引 3938 次 · h-index 25

代表论文

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations (2023 · Journal of Thoracic Oncology · 被引 53)
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC (2023 · Journal of Thoracic Oncology · 被引 44)
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition (2022 · The Journal of Clinical Pharmacology · 被引 21)
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial (2022 · Nature Communications · 被引 19)
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests (2023 · Journal of Molecular Diagnostics · 被引 15)
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial (2024 · JTO Clinical and Research Reports · 被引 14)